Mutis T - Search Results

1

Efficacy of host-dendritic cell vaccinations with or without minor histocompatibility antigen loading, combined with donor lymphocyte infusion in multiple myeloma patients.

Oostvogels R, Kneppers E, Minnema MC, Doorn RC, Franssen LE, Aarts T, Emmelot ME, Spierings E, Slaper-Cortenbach I, Westinga K, Goulmy E, Lokhorst HM, Mutis T. Oostvogels R, et al. Among authors: mutis t. Bone Marrow Transplant. 2017 Feb;52(2):228-237. doi: 10.1038/bmt.2016.250. Epub 2016 Nov 14. Bone Marrow Transplant. 2017. PMID: 27841858 Clinical Trial.

2

HLA class II restricted T-cell reactivity to a developmentally regulated antigen shared by leukemic cells and CD34+ early progenitor cells.

Mutis T, Schrama E, van Luxemburg-Heijs SA, Falkenburg JH, Melief CJ, Goulmy E. Mutis T, et al. Blood. 1997 Aug 1;90(3):1083-90. Blood. 1997. PMID: 9242539 Free article.

3

CD80-Transfected acute myeloid leukemia cells induce primary allogeneic T-cell responses directed at patient specific minor histocompatibility antigens and leukemia-associated antigens.

Mutis T, Schrama E, Melief CJ, Goulmy E. Mutis T, et al. Blood. 1998 Sep 1;92(5):1677-84. Blood. 1998. PMID: 9716596 Free article.

4

Feasibility of immunotherapy of relapsed leukemia with ex vivo-generated cytotoxic T lymphocytes specific for hematopoietic system-restricted minor histocompatibility antigens.

Mutis T, Verdijk R, Schrama E, Esendam B, Brand A, Goulmy E. Mutis T, et al. Blood. 1999 Apr 1;93(7):2336-41. Blood. 1999. PMID: 10090944 Free article.

5

Polyriboinosinic polyribocytidylic acid (poly(I:C)) induces stable maturation of functionally active human dendritic cells.

Verdijk RM, Mutis T, Esendam B, Kamp J, Melief CJ, Brand A, Goulmy E. Verdijk RM, et al. Among authors: mutis t. J Immunol. 1999 Jul 1;163(1):57-61. J Immunol. 1999. PMID: 10384099

6

Tetrameric HLA class I-minor histocompatibility antigen peptide complexes demonstrate minor histocompatibility antigen-specific cytotoxic T lymphocytes in patients with graft-versus-host disease.

Mutis T, Gillespie G, Schrama E, Falkenburg JH, Moss P, Goulmy E. Mutis T, et al. Nat Med. 1999 Jul;5(7):839-42. doi: 10.1038/10563. Nat Med. 1999. PMID: 10395333

7

The HA-2 minor histocompatibility antigen is derived from a diallelic gene encoding a novel human class I myosin protein.

Pierce RA, Field ED, Mutis T, Golovina TN, Von Kap-Herr C, Wilke M, Pool J, Shabanowitz J, Pettenati MJ, Eisenlohr LC, Hunt DF, Goulmy E, Engelhard VH. Pierce RA, et al. Among authors: mutis t. J Immunol. 2001 Sep 15;167(6):3223-30. doi: 10.4049/jimmunol.167.6.3223. J Immunol. 2001. PMID: 11544309

8

Hematopoietic system-specific antigens as targets for cellular immunotherapy of hematological malignancies.

Mutis T, Goulmy E. Mutis T, et al. Semin Hematol. 2002 Jan;39(1):23-31. doi: 10.1053/shem.2002.29248. Semin Hematol. 2002. PMID: 11799526 Review.

9

General T-cell receptor antagonists to immunomodulate HLA-A2-restricted minor histocompatibility antigen HA-1-specific T-cell responses.

den Haan JM, Mutis T, Blokland E, IJzerman AP, Goulmy E. den Haan JM, et al. Among authors: mutis t. Blood. 2002 Feb 1;99(3):985-92. doi: 10.1182/blood.v99.3.985. Blood. 2002. PMID: 11807003 Free article.

10

HLA class I-minor histocompatibility antigen tetramers select cytotoxic T cells with high avidity to the natural ligand.

Gillespie G, Mutis T, Schrama E, Kamp J, Esendam B, Falkenburg JF, Goulmy E, Moss P. Gillespie G, et al. Among authors: mutis t. Hematol J. 2000;1(6):403-10. doi: 10.1038/sj.thj.6200065. Hematol J. 2000. PMID: 11920221

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

145 results

Search Page

Filters